Log in

NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

$112.25
+6.13 (+5.78 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$106.00
Now: $112.25
$112.34
50-Day Range
$77.16
MA: $97.30
$112.23
52-Week Range
$34.39
Now: $112.25
$112.34
Volume317,995 shs
Average Volume570,668 shs
Market Capitalization$4.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.93 million
Book Value$5.86 per share

Profitability

Net Income$-98,420,000.00
Net Margins-2,698.66%

Miscellaneous

Employees63
Market Cap$4.43 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.


Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) issued its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analysts' expectations of $0.50 million. Mirati Therapeutics had a negative net margin of 2,698.66% and a negative return on equity of 48.60%. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

16 Wall Street analysts have issued 1-year target prices for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $130.00. On average, they anticipate Mirati Therapeutics' stock price to reach $107.21 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:
  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (12/14/2019)
  • 2. HC Wainwright analysts commented, "Our $117 price target is based on a sum-of-the-parts analysis determined by probability adjusted revenue forecasts for sitravatinib and MRTX849. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 20% POS for MRTX849, and our YE19 fully diluted net cash estimate of $8.00/share to arrive at our price target." (8/6/2019)

Has Mirati Therapeutics been receiving favorable news coverage?

Press coverage about MRTX stock has been trending neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Mirati Therapeutics.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 4,870,000 shares, a decrease of 9.0% from the November 14th total of 5,350,000 shares. Based on an average daily volume of 697,400 shares, the short-interest ratio is presently 7.0 days. Currently, 12.7% of the shares of the stock are sold short. View Mirati Therapeutics' Current Options Chain.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Exelixis (EXEL), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Netflix (NFLX), Tandem Diabetes Care (TNDM), Viking Therapeutics (VKTX) and Bausch Health Companies (BHC).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.36%), Orbimed Advisors LLC (1.36%), Eventide Asset Management LLC (0.76%), Pictet Asset Management Ltd. (0.68%), Emerald Advisers LLC (0.34%) and Emerald Mutual Fund Advisers Trust (0.33%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Chicago Equity Partners LLC, Meeder Asset Management Inc., Dowling & Yahnke LLC and Russell Investments Group Ltd.. Company insiders that have sold Mirati Therapeutics company stock in the last year include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Michael G Grey and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Pictet Asset Management Ltd., Man Group plc, Eventide Asset Management LLC and Columbus Circle Investors. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $112.25.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $4.43 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com/.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  643
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Fibonacci Channel

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel